Genmab — Juni 2017
-
Analytikerne har som GB siger ikke set lyset i Car-T som en fremtidig konkurrent til Dara. Måske det kommer på et tidspunkt.
-
Der skal ikke mange tilfælde af hjerneødem til før at man sendes tilbage i skammekrogen.
-
Næste store kurstrigger i Genmab bliver om Darzalex har effekt i lungekræft i kombi med Tecentriq. Til den tid er Car-T stadig meget usikkert. H1 2018 kan vi forvente noget fra lungekræft.
-
Ja
-
Men alle forventer meget gode frontline tal. Så det bliver ikke en mega trigger
-
The consistency, depth and durability of these patients’ responses coupled with a manageable safety profile is very exciting, and we believe will provide hope for patients in this setting.... Bluebirds PR på dette afslører også hvem de går efter. Nemlig pts uden andre muligheder.
-
Tak for dine indspark Solsen. Men bluebird er værd at holde øje med.
-
bluebird bio logobluebird bio Inc (NASDAQ:BLUE)‘s stock had its “buy” rating restated by research analysts at Jefferies Group LLC in a note issued to investors on Friday. They currently have a $88.00 price objective on the biotechnology company’s stock. Jefferies Group LLC’s price target points to a potential upside of 6.80% from the stock’s current price.
-
Spændende om der kommer en lille positiv markedsreaktion imorgen ovenpå ASCO.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind